Phathom Pharmaceuticals (PHAT) Consolidated Net Income (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Consolidated Net Income of -$28.0 million for Q2 2026, up 66.44% year-over-year from -$16.8 million in Q2 2025, and up 41.64% quarter-over-quarter from -$48.0 million in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Consolidated Net Income (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Consolidated Net Income for 9 consecutive years, with -$28.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Consolidated Net Income rose 66.44% year-over-year to -$28.0 million; the TTM figure through Jun 2026 stood at -$152.3 million (up 51.82% YoY), while the FY2025 annual figure was -$458.6 million, up 11.41% from the prior year.
- Consolidated Net Income advanced to -$28.0 million in Q2 2026 per PHAT's latest filing, from -$48.0 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$19.8 million in Q4 2024 and bottomed at -$118.7 million in Q3 2024.
- Historically, Consolidated Net Income has averaged -$58.7 million across 5 years, with a median of -$49.4 million in 2022.
- On a YoY basis, Consolidated Net Income climbed as much as 79.37% in 2024 and fell as far as 175.73% in 2024.
- Phathom Pharmaceuticals' Consolidated Net Income stood at -$47.4 million in 2022, then tumbled by 102.1% to -$95.9 million in 2023, then soared by 79.37% to -$19.8 million in 2024, then fell by 6.87% to -$21.1 million in 2025, then tumbled by 32.41% to -$28.0 million in 2026.
- Business Quant data shows PHAT's Consolidated Net Income at -$28.0 million in Q2 2026, -$48.0 million in Q1 2026, and -$21.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | -17.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.56 Mn |
| Mar 31, 2026 | -29.54 Mn |
| Dec 31, 2025 | -21.14 Mn |
| Sep 30, 2025 | -29.97 Mn |
| Jun 30, 2025 | -75.66 Mn |
| Mar 31, 2025 | -94.29 Mn |
| Dec 31, 2024 | -74.50 Mn |
| Sep 30, 2024 | -85.57 Mn |
| Jun 30, 2024 | -91.44 Mn |
| Mar 31, 2024 | -82.81 Mn |
| Dec 31, 2023 | -79.56 Mn |
| Sep 30, 2023 | -43.05 Mn |
| Jun 30, 2023 | -40.97 Mn |
| Mar 31, 2023 | -37.83 Mn |
| Dec 31, 2022 | -54.96 Mn |
| Sep 30, 2022 | -51.08 Mn |
| Jun 30, 2022 | -50.92 Mn |
| Mar 31, 2022 | -40.66 Mn |
| Dec 31, 2021 | -35.81 Mn |
| Sep 30, 2021 | -34.61 Mn |